ADVA-OPTICAL-NETWORKING
25.6.2020 09:02:04 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that the Central Bank of Austria is deploying its FSP 3000 technology in a new, highly reliable, ultra-secure data center interconnect (DCI) network. With capacity for up to 32Gbit/s Fibre Channel and 100Gbit/s Ethernet services, the infrastructure provides robust, high-speed disaster recovery and business continuity capabilities that are essential for mission-critical operations. It’s protected by ADVA’s ConnectGuard™ Optical encryption and the real-time assurance of the ADVA ALM fiber monitoring solution. ADVA’s open modular FSP 3000 platform ensures that the bank’s redundant point-to-point system is easily scalable and highly efficient with space and power consumption. The network was installed by ADVA’s partners Componet and dacoso, who are also providing ongoing support with maintenance and SLA management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200625005079/en/
“Our customers demand world-class services with unbeatable security and availability. That’s why we’re committed to harnessing the most innovative technology on the market. Built on the ADVA FSP 3000 and secured by ConnectGuard™ Optical encryption, our new DCI network supports the fastest, most advanced SAN connectivity available, ensuring mission-critical data is always accessible and fully protected,” said Daniela Karanitsch, head of IT operations, Central Bank of Austria. “This flexible, high-capacity solution empowers us to tackle huge increases in data demand while also making significant savings on rack space and power consumption. What’s more, its efficiency and sustainability is further enhanced by ADVA’s ALM fiber monitoring technology, which provides round-the-clock visibility and assurance of the entire network.”
The Central Bank of Austria’s new network can transport up to 200Gbit/s on a single wavelength. It supports a wide range of services on one platform, including 1, 10, 25, 40 and 100Gbit/s Ethernet as well as 8, 16 and 32Gbit/s Fibre Channel. That flexibility enables the bank to maximize efficiency as it responds to changing customer requirements. Austria’s most sensitive financial data is now being safeguarded by encryption at the lowest network layer, guaranteeing resilient protection with none of the latency and performance problems that come with other security methods. ADVA’s FSP 3000 ConnectGuard™ Optical was the first encryption solution on the market to support Fibre Channel speeds up to 32Gbit/s. It’s still the only one capable of such speeds to achieve BSI-approved status, enabling its use for EU and NATO restricted data.
“Our FSP 3000 platform gives the Central Bank of Austria exceptionally fast, agile and robust disaster recovery and business continuity capabilities. And with our ALM technology, it delivers precise, real-time insight into the bank’s fiber plant so that any impairments or breaks can be rapidly repaired with minimal disruption. In fact, our ALM has already repaid the bank’s investment by identifying an issue at the service provider end and preventing outages from occurring,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “For a major national bank leasing dark fiber, secure connectivity is of paramount importance. With the low-latency, physical-layer encryption of our FSP 3000 ConnectGuard™, customers throughout Austria can now be sure of a frictionless experience and complete peace of mind when accessing their financial data.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.adva.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005079/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
